AstraZeneca PLC (AZN.LN) said Wednesday the U.S. Food and Drug Administration has granted priority review of the drug company's application for approval of its blood cancer treatment acalabrutinib.
AstraZeneca made a new drug application for the treatment after a Phase II trial.
Continue Reading Below
The FDA grants priority review, which accelerates the assessment of drugs, to applications for medicines that, if approved, would offer a significant improvement in the treatment, diagnosis, or prevention of serious conditions.
Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
August 02, 2017 02:42 ET (06:42 GMT)